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Abstract
BACKGROUND—Congenital hydrocephalus is a condition characterized by accumulation of 
cerebrospinal fluid in the ventricles of the brain. Prenatal infections are risk factors for some birth 
defects. This pilot study investigated whether residual dried blood spots (DBS) could be used to 
assess infections as risk factors for birth defects by examining the associations between prenatal 
infection with Toxoplasma gondii (T. gondii) or cytomegalovirus (CMV) with congenital 
hydrocephalus.
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METHODS—Case-infants with hydrocephalus (N = 410) were identified among live-born infants 
using birth defects surveillance systems in California, North Carolina, and Texas. Control-infants 
without birth defects were randomly selected from the same geographic areas and time periods as 
case-infants (N = 448). We tested residual DBS from case- and control-infants for T. gondii 
immunoglobulin M and CMV DNA. When possible, we calculated crude odds ratios (cORs) and 
confidence intervals (CIs).
RESULTS—Evidence for prenatal T. gondii infection was more common among case-infants 
(1.2%) than control-infants (0%; p = 0.11), and evidence for prenatal CMV infection was higher 
among case-infants (1.5%) than control-infants (0.7%; cOR: 2.3; 95% CI: 0.48, 13.99).
CONCLUSIONS—Prenatal infections with T. gondii and CMV occurred more often among 
infants with congenital hydrocephalus than control-infants, although differences were not 
statistically significant. This pilot study highlighted some challenges in using DBS to examine 
associations between certain infections and birth defects, particularly related to reduced sensitivity 
and specimen storage conditions. Further study with increased numbers of specimens and higher 
quality specimens should be considered to understand better the contribution of these infections to 
the occurrence of congenital hydrocephalus.
Keywords
newborn dried blood spots; hydrocephalus; congenital infections; cytomegalovirus; Toxoplasma 
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INTRODUCTION
Maternal infection during pregnancy can adversely affect pregnancy outcomes. Known 
teratogenic pathogens include rubella, cytomegalovirus (CMV), lymphocytic 
choriomeningitis virus, and Toxoplasma gondii (T. gondii), the cause of toxoplasmosis 
(Bale, 2002, 2009; Jamieson et al., 2006; Ornoy and Diav-Citrin, 2006). Because infections 
with some agents (e.g., CMV and T. gondii) can be asymptomatic or lead to nonspecific 
symptoms, studies relying on maternal report of infection are unlikely to discern their 
potentially etiologic role (Bale, 2002; Jamieson et al., 2006; Rasmussen et al., 2007; Wright 
et al., 1997). To improve understanding of the association between maternal infections 
during pregnancy and the occurrence of congenital anomalies, a different approach is 
required.
Congenital hydrocephalus is a condition, present at birth, characterized by the accumulation 
of cerebrospinal fluid in the ventricles of the brain (McAllister, 2012). Without surgical 
intervention to relieve the pressure caused by excess fluid, major damage to the brain tissue 
occurs in most cases. Congenital hydrocephalus is generally diagnosed prenatally or at birth, 
but it can also remain undiagnosed until later in life (Van Landingham et al., 2009). A 
pooled prevalence estimate from birth defects surveillance data collected in Arkansas, 
California, Georgia, Iowa, Massachusetts, New York, North Carolina, Texas, and Utah 
indicates that congenital hydrocephalus occurs in ~6.73 per 10,000 live births (Honein et al., 
2012). While some cases of hydrocephalus are due to genetic causes, often no etiology is 
identified. T. gondii and CMV have the ability to infect the developing fetus and have been 
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identified as a rare cause of hydrocephalus, based primarily on case reports (James, 1992; 
Azam et al., 2001; Bale, 2002; Lipitz et al., 2002; Villena et al., 2010). Limited information 
is available to understand the magnitude of the contribution these infections make to the 
occurrence of congenital hydrocephalus on a population level.
Newborn residual dried blood spots (DBS) are stored either short- or long-term by many 
newborn screening programs after their initial screening use (Olney et al., 2006; Therrell et 
al., 2011; Therrell and Hannon, 2012) and represent an underutilized population-based 
resource for retrospective studies of in utero exposures to prenatal infections and other 
maternal exposures (Henderson et al., 1997; Snijdewind et al., 2012). This study was 
designed as a pilot to investigate the utility of DBS to assess infections during pregnancy as 
risk factors for hydrocephalus.
MATERIALS AND METHODS
Case Identification
Case-infants with hydrocephalus (N = 410) were retrospectively identified among live-born 
infants using population-based birth defects surveillance systems in CA, NC, and TX. The 
CA Birth Defects Monitoring Program reported cases born between 1995 and 2003 to 
mothers who were residents of 13 CA counties (Los Angeles, Orange, San Francisco, Santa 
Clara, San Diego, Fresno, Kern, Kings, Madera, Merced, San Joaquin, Stanislaus, and 
Tulare). The NC Birth Defects Monitoring Program reported cases born throughout the state 
between 2003 and 2005, and the TX Birth Defects Registry reported cases born throughout 
the state between 2003 and 2004. All identified cases were reviewed by a clinical geneticist 
with birth defects expertise. Cases of hydrocephalus due to a structural brain lesion or due to 
a known genetic cause or an intraventricular hemorrhage were excluded. Infants without 
birth defects were randomly selected from the same geographic area and time period as 
case-infants to serve as controls (N = 448). The institutional review boards at each state and 
the Centers for Disease Control and Prevention (CDC) approved this study.
Specimen Testing
A single residual DBS of ~1.3 cm in diameter was obtained from storage in CA, NC, and 
TX for each case-and control-infant. Specimens were transported under ambient conditions 
to the CDC. Upon receipt, all samples were stored at −20 °C before analysis. Before 
transport to CDC, the CA DBS samples were stored in ideal conditions (−20 °C, with 
desiccant, and exposed to, <30% humidity; Mei et al., 2011). In contrast, the NC and TX 
DBS samples were stored under ambient temperatures without desiccant; TX samples were 
stored in a dehumidified laboratory. Before being sent to CDC for analysis, specimens were 
stripped of all personal identifiers and labeled with a unique ID number (Mei et al., 2011). 
Individual level information was only maintained for four variables: case/control status, 
maternal state residence at delivery (CA, NC, and TX), maternal race/ethnicity (non-
Hispanic white, non-Hispanic Black, Hispanic, and other), and maternal age (<30 years, ≥30 
years). To ensure quality control, known T. gondii-positive (n = 13) and negative (n = 10) 
DBS samples, and known CMV-positive (n = 13) and negative (n = 10) DBS samples were 
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added into the study sample. Technicians performing the assays were blinded to case/control 
and quality control sample status.
Presence of T. gondii immunoglobulin M (IgM) was tested using the Neonatal Toxoplasma-
screen AutoDelfia® kit (Kankaanpää et al.; PerkinElmer Life and Analytical Sciences, 
Turku, Finland) using a manual protocol (Zhou et al., 2005). Briefly, 3.2 mm disks were 
punched from the DBS and placed in Nunc cryotubes™ (Thermo Fisher Scientific, 
Rochester, NY). Specimens were eluted overnight in the assay buffer at 4 °C. The cutoff for 
the presence of T. gondii IgM was 20 IU/ml (Zhou et al., 2005; Mei et al., 2011). For 
samples above the cutoff point, the infant was presumed infected with T. gondii in utero. 
While all specimens were tested for T. gondii, residual DBS samples from NC and TX were 
stored at ambient temperature and humidity, allowing IgM antibodies in DBS to degrade, 
prohibiting reliable T. gondii IgM elution. Therefore, T. gondii IgM results presented are 
limited to those from CA (n = 515; Mei et al., 2011).
CMV DNA was extracted from DBS using a modified thermal shock method (Shibata et al., 
1994; Barbi et al., 1996). Three 3.2 mm punches were placed in a 2 ml microfuge tube with 
60 μl of Glutamine-free Minimum Essential Medium and soaked for 2 hr at room 
temperature, then incubated at 55 °C for 1 hr, then 100 °C for 7 min, and then transferred to 
ice for rapid cooling. The tubes were stored at −80 °C until they were used for polymerase 
chain reaction (PCR) analysis. Presence of CMV DNA was established using Taqman-based 
PCR targeting the CMV glycoprotein B region (Boppana et al., 2005). An internal positive 
control synthetic template (ABI, Grand Island, NY) was included in each reaction as an 
indicator for the presence of PCR inhibitors. Samples for which the internal control for the 
PCR reaction failed were set as missing.
Analysis
Prevalence of infection with T. gondii and CMV were examined overall and by state of 
birth. Differences in population characteristics between case-infants and control-infants 
were analyzed using chi-square tests of association or Fisher’s exact tests. Data were sparse, 
but when possible, crude odds ratios (cORs) and confidence intervals (CIs) were calculated 
using Fisher’s exact test to estimate the association between each infection and congenital 
hydrocephalus. All analyses were performed in SAS 9.3 (Cary, NC).
RESULTS
Demographic Characteristics
In total, 858 DBS were sent to CDC with 410 samples from infants with hydrocephalus 
(case-infants) and 448 infants with no major birth defects (control-infants). Approximately 
two-thirds of mothers were <30 years of age, and over three-quarters were non-Hispanic 
white or Hispanic. Overall, neither maternal age nor maternal race/ethnicity differed by case 
status (Table 1).
By state of maternal residence, 515 DBS were from infants in CA, 160 were from NC, and 
183 were from TX. Case- and control-mothers were not statistically different by maternal 
age in any of the three sites. There was no significant difference in maternal race/ethnicity 
Simeone et al. Page 4













between cases and controls in CA or NC, but in TX, case-infants were more likely to be 
non-Hispanic Black than control-infants (Table 1).
T. gondii Antibody Detection from Residual DBS
T. gondii IgM testing correctly identified 10 of 10 negative controls (specificity = 100%) 
and 13 of 13 positive controls (sensitivity = 100%). Of the 245 case-infants from CA, T. 
gondii IgM was detected in three residual DBS (1.2%; Table 2). None of the residual DBS 
from control-infants had detectable levels of T. gondii IgM (Table 2). A frequency of three 
cases with T. gondii infection versus zero controls was not different statistically (p = 0.11).
CMV Detection from Residual DBS
CMV DNA testing correctly identified 10 of 10 negative controls (specificity = 100%) and 
12 of 13 positive controls (sensitivity = 92%). Samples from all sites were tested for CMV 
DNA. Seventeen samples were set to missing and excluded from the analysis because the 
internal control for the PCR reaction failed. After testing for T. gondii, three residual DBS 
from NC had insufficient samples remaining for CMV PCR analysis, yielding a total sample 
size of 838 DBS analyzed. Overall, six of 396 case-infants with hydrocephalus (1.5%) and 
three of 442 control-infants without birth defects (0.7%) had residual DBS that tested 
positive for CMV DNA (cOR: 2.3; p = 0.32; 95% CI: 0.48, 13.99; Table 2).
DISCUSSION
Newborns with congenital hydrocephalus were more likely to have evidence of a CMV or T. 
gondii infection at delivery compared with newborns without congenital hydrocephalus, but 
differences were not statistically significant. The lack of statistical significance might be 
related to the small number of samples available, the quality of the samples available, or 
might suggest that a relatively small proportion of congenital hydrocephalus is related to 
these two infections. A preliminary power analysis for samples of 500 cases and 500 
controls, assuming an estimated prevalence among controls of 0.01 (CMV) and 0.002 (T. 
gondii), indicated that the minimum odds ratios detectable for the association of congenital 
hydrocephalus with either maternal CMV or T. gondii were 3.78 and 10.6, respectively. 
While this pilot study did not identify any statistically significant association of CMV or T. 
gondii with congenital hydrocephalus, it did demonstrate some of the challenges in assessing 
the role of prenatal infections in the etiology of congenital disorders, which include sample 
size, quality of samples, and the variation in prevalence of infection between populations. 
This approach might be most useful when higher quality samples are available and when 
conducting research in populations with a higher prevalence of these infections.
Birth prevalence of congenital CMV infection in the United States ranges from 0.5 to 1.3%, 
and CMV is estimated to infect 30,000–40,000 infants annually (Ross and Boppana, 2005; 
Dollard et al., 2007). Some of the health problems in the neonate associated with intrauterine 
infection with CMV include chorioretinitis, intrauterine growth restriction, and sensorineural 
hearing loss and vision impairment (Ornoy and Diav-Citrin, 2006). The rate of newborn 
infection with T. gondii is estimated to be one per 10,000 live births (Jara et al., 2001; Bale, 
2002). The adverse effects of intrauterine infection with T. gondii on the neonate include 
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chorioretinitis and cerebral calcifications (Bale, 2002; Ornoy and Diav-Citrin, 2006; Olariu 
et al., 2011). The prevalence of CMV and T. gondii infections vary by demographic factors, 
with older age and lower socioeconomic status being associated with infection (Jones et al., 
2007; Bate et al., 2010). In women with normal immune systems, risk of fetal infection is 
highest among mothers who acquire a primary CMV or T. gondii infection during pregnancy 
(Bale, 2002; Kravetz and Federman, 2005; Kenneson and Cannon, 2007).
Newborn screening programs in most states store residual DBS for at least one year; at least 
14 programs store residual DBS up to 21 years (Therrell and Hannon, 2012). These residual 
DBS can potentially be used to diagnose retrospectively congenital infections after the 
occurrence of adverse health outcomes, to screen for congenital infections, or for 
retrospective population-based analyses of birth defects or other conditions (Choi et al., 
2009; Therrell et al., 2011). A challenge to using residual DBS is that storage conditions are 
often not ideal, thus limiting the research studies that can be performed (Therrell et al., 
1996). In addition, the availability of residual DBS for research varies by state (Therrell et 
al., 2011; Therrell and Hannon, 2012).
This study had several strengths. Case-infants were identified using established population-
based birth defects surveillance systems, and control-infants were drawn from the same 
source population and time period as case-infants. Additionally, abstracted medical records 
of cases were reviewed by a clinical geneticist to ensure a consistent case-definition for 
congenital hydrocephalus was used for all case-infants. Appropriate case classification of 
congenital hydrocephalus is important, as the disease is multifactorial and can arise from 
numerous causes.
Limitations of the study include lack of ideal storage conditions for ~40% of the residual 
DBS. T. gondii IgM recovery was significantly impaired in samples stored in ambient 
conditions (Mei et al., 2011), leading to the exclusion of samples from NC and TX for T. 
gondii antibody testing. Moreover, CMV DNA viral load is reduced, although still 
recoverable, after 2 years (Atkinson et al., 2009). Second, previous studies have indicated 
that neonatal screening for T. gondii IgM using DBS detects ~52–87% of infected newborns 
(Lebech et al., 1999; Paul et al., 2000; Gilbert et al., 2007). Similarly, the sensitivity of 
CMV DBS DNA testing approaches 100% when testing symptomatic newborns (Barbi et 
al., 1996; Snijdewind et al., 2012), but ranges from ~30 to 80% when testing unselected 
population-based newborns (Soetens et al., 2008; Boppana et al., 2010). While this suggests 
some case- and control-infants with T. gondii or CMV infection might have been missed 
with an approach that used residual DBS, the study was most likely to miss those with CMV 
infection who had a low viral load and thus were at low risk for clinical sequelae related to 
the infection. Third, while this was a population-based study, it was a pilot with a small 
sample size, and the estimates for the prevalence of T. gondii and CMV infections are 
imprecise. The data were too sparse to be stratified by race/ethnicity, which is problematic 
given that case-infants from Texas were more likely than controls to be non-Hispanic black 
and CMV is more common among non-Hispanic blacks (Bate et al., 2010). A larger number 
of DBS specimens from both case-infants and control-infants, higher quality samples, or a 
population with a higher prevalence of infection would be needed to better understand the 
association between congenital hydrocephalus and these infections during pregnancy. 
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Finally, DBS provide no information regarding maternal infection status before pregnancy 
or of the timing of the infection during pregnancy. These factors could greatly influence the 
occurrence and severity of any subsequent sequelae, such as congenital hydrocephalus.
In summary, this pilot study observed results consistent with the hypothesis that T. gondii 
and CMV infections during pregnancy may be more frequent among infants with congenital 
hydrocephalus compared to unaffected infants, although these results were not significant. 
Future studies using DBS from larger samples of case-infants and control-infants would be 
needed to understand better the potential contribution of T. gondii or CMV infection during 
pregnancy to the occurrence of congenital hydrocephalus in the population. Residual DBS 
represent an important, population-based resource that can be used to understand better the 
association between infections during pregnancy and adverse birth outcomes including 
major birth defects. For infections that are predominantly asymptomatic or present with 
nonspecific symptoms, objective testing such as that available using DBS will be one of the 
few paths available to evaluate the etiologic role of these infections. Such studies would be 
facilitated by more widespread adoption by state newborn metabolic screening programs of 
the recommended procedures for storing residual DBS.
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